News Image

Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025

Provided By GlobeNewswire

Last update: Aug 31, 2025

Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simultaneous Publication in the Journal of the American College of Cardiology

Read more at globenewswire.com

CYTOKINETICS INC

NASDAQ:CYTK (11/6/2025, 8:00:01 PM)

After market: 60.28 -0.02 (-0.03%)

60.3

+1.11 (+1.88%)



Find more stocks in the Stock Screener

Follow ChartMill for more